Results 81 to 90 of about 212,261 (301)
Oncologic Emergencies: Immune-Based Cancer Therapies and Complications [PDF]
, 2020 Cancer therapies have undergone several recent advancements. Current cancer treatments include immune-based therapies comprised of checkpoint inhibitors, and adoptive immunotherapy; each treatment has the potential for complications that differ from ...
Brém, Elizabeth +2 more
core
The convergence of radiation and immunogenic cell death signaling pathways. [PDF]
, 2012 Ionizing radiation (IR) triggers programmed cell death in tumor cells through a variety of highly regulated processes. Radiation-induced tumor cell death has been studied extensively in vitro and is widely attributed to multiple distinct mechanisms ...
Barcellos-Hoff, Mary H +4 more
core +2 more sources
Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer
Molecular Oncology, EarlyView.Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni +11 more
wiley +1 more source
Widespread Hypertrophic Lichen Planus following Programmed Cell Death Ligand 1 Blockade
Case Reports in Dermatology, 2020 Hypertrophic lichen planus (HLP) may not have the typical histological findings of lichen planus and often mimics squamous cell carcinoma (SCC). Distinguishing between the two can pose a diagnostic challenge.
Caitlyn N. Myrdal +2 more
doaj +1 more source
Molecules, 2022 New biphenyl-based chimeric compounds containing pomalidomide were developed and evaluated for their activity to inhibit and degrade the programmed cell death-1/programmed cell death- ligand 1 (PD-1/PD-L1) complex.
Shabnam Shaabani +12 more
doaj +1 more source
Molecular Oncology, EarlyView.Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau +8 more
wiley +1 more source
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity [PDF]
Nature Communications, 2016 AbstractExtracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1) leads to tumour-associated immune escape. Here we show that the immunosuppression activity of PD-L1 is stringently modulated by ubiquitination and N-glycosylation.
Chia-Wei Li +23 more
openaire +3 more sources
Acta Dermato-VenereologicaBeyond established anti-programmed cell death protein 1/programmed cell death ligand 1 immunotherapy, T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domain (TIGIT) and its ligand CD155 are promising novel ...
Anke S. Lonsdorf +9 more
doaj +1 more source
Respiratory Medicine Case Reports, 2020 We herein report a non-smoking 81-year-old man with advanced synchronous multiple primary lung cancers (SMPLC), containing squamous cell carcinoma with strong programmed death-ligand 1 expression in the middle lobe and adenocarcinoma with epidermal ...
Hirokazu Tokuyasu +5 more
doaj +1 more source
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
BMC Cancer, 2022 Background Mantle cell lymphoma (MCL) has remained incurable in most patients. The expression of PD-L1 as a prognostic and predictive marker has not been fully evaluated in MCL.
Fereshteh Ameli +3 more
doaj +1 more source